Top

Systematic Reviews

Published in:

Open Access 01-12-2021 | Breast Cancer | Research

The impact of different preanalytical methods related to CA 15-3 determination in frozen human blood samples: a systematic review

Authors: Luigi Coppola, Alessandra Cianflone, Katia Pane, Monica Franzese, Peppino Mirabelli, Marco Salvatore

Published in: Systematic Reviews | Issue 1/2021

Abstract

Background

The determination of CA 15-3 is useful for monitoring breast cancer patients. Several retrospective studies determined CA 15-3 levels in frozen samples to evaluate the sensitivity and specificity of novel biomarkers in relation to breast cancer; however, freeze-thaw cycles, as well as preanalytical variables before sample storage, are not always reported. Here, we analyzed the current scientific literature to identify possible critical aspects related to CA 15-3 determination in frozen-stored human serum/plasma samples.

Methods

We obtained data from 4 different bibliographic databases: Web of Science, Embase, PubMed, and Cochrane Library. We followed the PRISMA guidelines to screen and select the eligible articles discussed in the final revision.

Results

Initially, 674 scientific papers were evaluated, and after the application of the screening and eligibility criteria, 18 studies were included in the qualitative synthesis. The analysis reported an important level of heterogeneity concerning the preanalytical phase before sample storage.

Conclusion

Although advances in healthcare have been achieved using certified workflows in medical diagnostics, standardized preanalytical processes are not always applied when referring to frozen-stored biosamples. Biobanks will guarantee the best possible conditions for the storage of human biological samples to be used in clinical research. The use of certified bioresources will favor the optimal development and introduction of new disease biomarkers.

Available only for authorised users

Kamtchum-Tatuene J, Jickling GC. Blood biomarkers for stroke diagnosis and management. Neuromolecular Med. 2019;21(4):344–68. https://doi.org/10.1007/s12017-019-08530-0.CrossRefPubMedPubMedCentral

Kilgour E, Rothwell DG, Brady G, Dive C. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell. 2020;37(4):485–95. https://doi.org/10.1016/j.ccell.2020.03.012.CrossRefPubMed

Smaldone G, Beneduce G, Incoronato M, Pane K, Franzese M, Coppola L, et al. KCTD15 is overexpressed in human childhood B-cell acute lymphoid leukemia. Sci Rep. 2019;9(1):20108. https://doi.org/10.1038/s41598-019-56701-7.CrossRefPubMedPubMedCentral

Pane K, Mirabelli P, Coppola L, Illiano E, Salvatore M, Franzese M. New roadmaps for non-muscle-invasive bladder cancer with unfavorable prognosis. Front Chem. 2020;8. https://doi.org/10.3389/fchem.2020.00600.

Coppola L, Cianflone A, Grimaldi AM, Incoronato M, Bevilacqua P, Messina F, et al. Biobanking in health care: evolution and future directions. J Transl Med. 2019;17(1):172. https://doi.org/10.1186/s12967-019-1922-3.CrossRefPubMedPubMedCentral

Hilkens J, Vos HL, Wesseling J, Peterse J, Storm J, Boer M, et al. The expression levels of episialin in human carcinomas are sufficiently high to potentially interfere with adhesion and promote metastasis. Breast Cancer Adv Biol Ther. 1996:281–288.

Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK. Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta Rev Cancer. 2011;1815(2):224–40. https://doi.org/10.1016/j.bbcan.2011.01.001.CrossRef

Li JX, Liu LY, Feng ZW, Wang X, Huang YB, Dai HJ, et al. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Breast Cancer. 2020;27(4):621–30. https://doi.org/10.1007/s12282-020-01058-3.

Le Rhun E, Kramar A, Salingue S, Girot M, Rodrigues I, Mailliez A, et al. CSF CA 15-3 in breast cancer-related leptomeningeal metastases. J Neurooncol. 2014;117(1):117–24. https://doi.org/10.1007/s11060-014-1361-1.CrossRefPubMed

10.

Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12):E11–79. https://doi.org/10.1373/clinchem.2008.105601.CrossRefPubMed

11.

Shao YB, Sun XF, He YN, Liu CJ, Liu H. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS One. 2015;10(7). https://doi.org/10.1371/journal.pone.0133830.

12.

Wu DW, Li YM, Wang F. How long can we store blood samples: a systematic review and meta-analysis. Ebiomedicine. 2017;24:277–85. https://doi.org/10.1016/j.ebiom.2017.09.024.CrossRefPubMedPubMedCentral

13.

Gunawardena D, Jayaweera S, Madhubhashini G, Lokumarakkala DD, Senanayake SJ. Reliability of parameters of complete blood count with different storage conditions. J Clin Lab Anal. 2017;31(2).

14.

Hanon EA, Sturgeon CM, Lamb EJ, PTH ISDWG. Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review. Clin Chem Lab Med. 2013;51(10):1925–41. https://doi.org/10.1515/cclm-2013-0315.CrossRefPubMed

15.

Bonilla-Sepúlveda ÓA. Tumor markers in breast cancer. Systematic review. Ginecol Obstet Méx. 2020;88(12):860–9.

16.

Fu YJ, Li H. Assessing clinical significance of serum CA15-3 and carcinoembryonic antigen (CEA) levels in breast cancer patients: a meta-analysis. Med Sci Monit. 2016;22:3154–62. https://doi.org/10.12659/MSM.896563.CrossRefPubMedPubMedCentral

17.

Wu Q, Li M, Zhang S, Chen L, Gu X, Xu F. Clinical diagnostic utility of CA 15-3 for the diagnosis of malignant pleural effusion: a meta-analysis. Exp Ther Med. 2015;9(1):232–8. https://doi.org/10.3892/etm.2014.2039.CrossRefPubMed

18.

Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7).

19.

Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531–48. https://doi.org/10.1038/nrclinonc.2017.14.CrossRefPubMed

20.

Spoorenberg SMC, Vestjens SMT, Voorn GP, van Moorsel CHM, Meek B, Zanen P, et al. Course of SP-D, YKL-40, CCL18 and CA 15-3 in adult patients hospitalised with community-acquired pneumonia and their association with disease severity and aetiology: a post-hoc analysis. PLoS One. 2018;13(1).

21.

Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

22.

Chukwurah E, Emele F, Iyare F. Breast cancer in Nigerian women: evaluating the utility of circulating immune complexes and cancer antigens (CA 15-3 and CA 27.29) in disease surveillance. Res J Immunol. 2018;11:7–14.CrossRef

23.

Mahmood M, Haq MF, Nizami NA, Akram S, Choudhry N, Yasmin R. Comparison of serum ferritin with carbohydrate antigen 15-3 (CA 15-3) in breast cancer patients in Pakistan. Pak J Med Health Sci. 2016;10(4):1384–9.

24.

Said NM. Three gold indicators for breast cancer prognosis: a case-control study with ROC analysis for novel ratios related to CBC with (ALP and LDH). Mol Biol Rep. 2019;46(2):2013–27. https://doi.org/10.1007/s11033-019-04650-9.CrossRefPubMed

25.

Moazzezy N, Farahany TZ, Oloomi M, Bouzari S. Relationship between preoperative serum CA15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pac J Cancer Prev. 2014;15(4):1685–8. https://doi.org/10.7314/APJCP.2014.15.4.1685.CrossRefPubMed

26.

El-Moneim Ebied SA, El-Moneim NAA, Hewala TL, Anwar MM, Rabi SM. The diagnostic, prognostic and follow-up value of serum Bcl-2, Bax and p53 proteins in breast cancer patients: a comparison with serum CA 15-3. Middle East J Cancer. 2013;4(2):51–62.

27.

Svobodova S, Kucera R, Fiala O, Karlikova M, Narsanska A, Zednikova I, et al. CEA, CA 15-3, and TPS as prognostic factors in the follow-up monitoring of patients after radical surgery for breast cancer. Anticancer Res. 2018;38(1):465–9. https://doi.org/10.21873/anticanres.12245.CrossRefPubMed

28.

Pedersen AC, Sorensen PD, Jacobsen EH, Madsen JS, Brandslund I. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clin Chem Lab Med. 2013;51(7):1511–9. https://doi.org/10.1515/cclm-2012-0488.CrossRefPubMed

29.

Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Stieber P. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. Clin Chim Acta. 2015;440:16–22. https://doi.org/10.1016/j.cca.2014.11.001.CrossRefPubMed

30.

Sen S, Kuru O, Akbayir O, Oguz H, Yasasever V, Berkman S. Determination of serum CRP, VEGF, Leptin, CK-MB, CA-15-3 and IL-6 levels for malignancy prediction in adnexal masses. J Turk Ger Gynecol Assoc. 2011;12(4):214–9. https://doi.org/10.5152/jtgga.2011.54.CrossRefPubMedPubMedCentral

31.

Metwally FM, El-mezayen HA, Ahmed HH. Significance of vascular endothelial growth factor, interleukin-18 and nitric oxide in patients with breast cancer: correlation with carbohydrate antigen 15.3. Med Oncol. 2011;28:S15–21. https://doi.org/10.1007/s12032-010-9657-2.

32.

Hewala TI, Abd El-Monaim NA, Anwar M, Ebied SA. The clinical significance of serum soluble Fas and p53 protein in breast cancer patients: comparison with serum CA 15-3. Pathol Oncol Res. 2012;18(4):841–8. https://doi.org/10.1007/s12253-012-9512-1.CrossRefPubMed

33.

Zajkowska M, Gacuta E, Lubowicka E, Szmitkowski M, Lawicki S. Can VEGFR-3 be a better tumor marker for breast cancer than CA 15-3? Acta Biochim Pol. 2020;67(1):25–9. https://doi.org/10.18388/abp.2020_2873.CrossRefPubMed

34.

Zaleski M, Kobilay M, Schroeder L, Debald M, Semaan A, Hettwer K, et al. Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA. Oncotarget. 2018;9(32):22523–36. https://doi.org/10.18632/oncotarget.25077.CrossRefPubMedPubMedCentral

35.

Tang Z, Li L, Shen L, Shen X, Ju S, Cong H. Diagnostic value of serum concentration and integrity of circulating cell-free DNA in breast cancer: a comparative study with CEA and CA 15-3. Lab Med. 2018;49(4):323–8. https://doi.org/10.1093/labmed/lmy019.CrossRefPubMed

36.

Christenson RH, Cervelli DR, Sterner J, Bachmann LM, Rebuck H, Gray J, et al. Analytical performance and clinical concordance of the cancer biomarkers CA 15-3, CA 19-9, CA 125 II, carcinoembryonic antigen, and alpha-fetoprotein on the Dimension Vista (R) System. Clin Biochem. 2011;44(13):1128–36. https://doi.org/10.1016/j.clinbiochem.2011.06.009.CrossRefPubMed

37.

Saba MA, Valeh T, Ehteram H, Haddad Kashani H, Ghazi ZM. Diagnostic value of neuron-specific enolase (NSE) and cancer antigen 15-3 (CA 15-3) in the diagnosis of pleural effusions. Asian Pac J Cancer Prev. 2017;18(1):257–61.PubMedPubMedCentral

38.

Laidi F, Bouziane A, Lakhdar A, Khabouze S, Amrani M, Rhrab B, et al. Significant correlation between salivary and serum Ca 15-3 in healthy women and breast cancer patients. Asian Pac J Cancer Prev. 2014;15(11):4659–62. https://doi.org/10.7314/APJCP.2014.15.11.4659.CrossRefPubMed

39.

Ercan S, Kaymaz O, Yucel N, Orcun A. Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study. Arch Gynecol Obstet. 2012;285(3):579–84. https://doi.org/10.1007/s00404-011-2025-4.CrossRefPubMed

40.

Flores CFY, de Las Mercedes Hurtado Pineda A, Bonilla VMC, Saenz-Flor K. Sample management: stability of plasma and serum on different storage conditions. Ejifcc. 2020;31(1):46–55.PubMedPubMedCentral

41.

Cuhadar S, Koseoglu M, Atay A, Dirican A. The effect of storage time and freeze-thaw cycles on the stability of serum samples. Biochem Med. 2013;23(1):70–7. https://doi.org/10.11613/bm.2013.009.CrossRef

42.

Hewitt R, Watson P. Defining biobank. Biopreserv Biobank. 2013;11(5):309–15. https://doi.org/10.1089/bio.2013.0042.CrossRefPubMed

43.

Hartman V, Castillo-Pelayo T, Babinszky S, Dee S, Leblanc J, Matzke L, et al. Is your biobank up to standards? A review of the National Canadian Tissue Repository Network required operational practice standards and the controlled documents of a certified biobank. Biopreserv Biobank. 2018;16(1):36–41. https://doi.org/10.1089/bio.2017.0065.CrossRefPubMed

44.

Schenk M, Huppertz B, Obermayer-Pietsch B, Kastelic D, Hormann-Kropfl M, Weiss G. Biobanking of different body fluids within the frame of IVF-a standard operating procedure to improve reproductive biology research. J Assist Reprod Genet. 2017;34(2):283–90. https://doi.org/10.1007/s10815-016-0847-5.CrossRefPubMed

Title: The impact of different preanalytical methods related to CA 15-3 determination in frozen human blood samples: a systematic review
Authors: Luigi Coppola
Alessandra Cianflone
Katia Pane
Monica Franzese
Peppino Mirabelli
Marco Salvatore
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Biomarkers
Published in: Systematic Reviews / Issue 1/2021
Electronic ISSN: 2046-4053
DOI: https://doi.org/10.1186/s13643-021-01631-7

At a glance: The STEP trials

Springer Medicine

The impact of different preanalytical methods related to CA 15-3 determination in frozen human blood samples: a systematic review

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Effect modification of the association between comorbidities and severe course of COVID-19 disease by age of study participants: a systematic review and meta-analysis

Treatment of eating disorders in older people: a systematic review

Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality

The association between hospital financial performance and the quality of care—a scoping review protocol

Normative beliefs and values that shape care-seeking behaviours for skilled birth attendance (SBA) during birthing by mothers in Africa: a scoping review protocol

Involvement of Indigenous young people in the design and evaluation of digital mental health interventions: a scoping review protocol